| |
|
|
|
|
|
|
| |
  |
|
| |
Research & Development
Research at Apotex includes the development of both generic
and innovative pharmaceuticals.
New generic products have been a critical component of
Apotex’s growth and have resulted in the development of
substantial expertise in formulation development, synthetic
and analytical chemistry.
Research on new chemical entities is carried out by
ApoPharma Inc., a Subsidiary of Apotex, where our current
focus is in the areas of hematology, neurodegenerative
diseases and psoriasis. Apotex's first innovative drug, Ferriprox™, is approved in over 50 countries for treating
iron overload in Thalassemia. More recently, extensive
research has begun on developing permeant iron chelators for
the treatment of several neurodegenerative diseases where
the impact of modifying intracellular iron metabolism is
being studied both in animals and humans. Our newest area of
research, psoriasis, will see ApoPharma initiate clinical
trials in 2008 to evaluate the safety and efficacy of a
novel dipeptide that has demonstrated a remarkable safety
profile in animal toxicity testing.
R & D expenditures for Apotex in 2006 was over $178 million,
representing close to 20% of sales, placing Apotex in the
top 12 research and development companies in Canada and the
top pharmaceutical company.
|
|
|